Drug Profile
Research programme: negamycin analogues - Appili Therapeutics
Alternative Names: ATI-1503Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Appili Therapeutics
- Class Anti-infectives; Antibacterials; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Gram-negative-infections in USA
- 15 Jun 2020 Negamycin analogues are still in preclinical trials for Gram-negative infections in USA (Appili Therapeutics pipeline, June 2020)
- 28 May 2020 No recent reports of development identified for preclinical development in Gram-negative-infections in USA